Maartje W. Rohaan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maartje W. Rohaan has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- John B. A. G. Haanen
The Netherlands Cancer Institute
10 shared publications - Inge Jedema
Division of Molecular Oncology and Immunology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
6 shared publications - Marco Donia
National Center for Cancer Immune Therapy, Department of Oncology Copenhagen University Hospital – Herlev and Gentofte Herlev Denmark
6 shared publications - Troels Holz Borch
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
6 shared publications - Bastiaan Nuijen
Netherlands Cancer Institute 5 Division of Pharmacy and Pharmacology Amsterdam, the Netherlands
5 shared publications - Inge Marie Svane
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
5 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Supplementary Table S1: Overview of Antibodies Used for Flow Cytometry and Phenotyping. Supplementary Table S2: Overview of Antibodies Used for the Co-culture Assays and Intracellular Cytokine Staining Supplementary Table S3: Baseline Characteristics and Clinical Response Data Supplementary Table S4: Phenotypic Composition of the infused TIL-IMP (% of parent with IQR) Supplementary Table S5: Absolute numbers of TIL-IMP subsets infused (median cell count with IQR) Supplementary Table S6: Absolute number of TIL-IMP, CD3+, CD4+TCRαβ+, and CD8+TCRαβ+ T cells infused and their correlation with PFS. Supplementary Table S7: Frequency of CD3+, CD4+TCRαβ+, and CD8+TCRαβ+ T cells infused and their correlation with PFS Supplementary Table S8: Baseline characteristics of patients included in the functional sub-analysis Supplementary Table S9: Comparison of baseline characteristics for patients with and without autologous TCLs Supplementary Table S10: Comparison of baseline characteristics for patients with high and low baseline MTV
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Supplementary Table S1: Overview of Antibodies Used for Flow Cytometry and Phenotyping. Supplementary Table S2: Overview of Antibodies Used for the Co-culture Assays and Intracellular Cytokine Staining Supplementary Table S3: Baseline Characteristics and Clinical Response Data Supplementary Table S4: Phenotypic Composition of the infused TIL-IMP (% of parent with IQR) Supplementary Table S5: Absolute numbers of TIL-IMP subsets infused (median cell count with IQR) Supplementary Table S6: Absolute number of TIL-IMP, CD3+, CD4+TCRαβ+, and CD8+TCRαβ+ T cells infused and their correlation with PFS. Supplementary Table S7: Frequency of CD3+, CD4+TCRαβ+, and CD8+TCRαβ+ T cells infused and their correlation with PFS Supplementary Table S8: Baseline characteristics of patients included in the functional sub-analysis Supplementary Table S9: Comparison of baseline characteristics for patients with and without autologous TCLs Supplementary Table S10: Comparison of baseline characteristics for patients with high and low baseline MTV
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Purpose:Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is a highly personalized cancer immunotherapy. In the randomized phase III clinical trial [TIL-Netherlands Cancer Institute (NKI)/National Center for Cancer Immune Therapy (CCIT)], TIL therapy significantly improved progression-free survival (PFS) compared with ipilimumab in patients with unresectable stage IIIC and IV cutaneous melanoma. This study aimed to define the phenotypic and functional characteristics of the infused TIL associated with the best overall response (BOR) and PFS. Experimental Design:Using flow cytometry, we profiled infusion products from all 80 patients treated with TILs in the TIL-NKI/CCIT trial and correlated the results with BOR and PFS. We established autologous tumor cell lines from 24 patients and assessed the antitumor reactivity of the infused CD4+ and CD8+ T cells through coculture assays and intracellular cytokine staining. We quantified tumor-reactive TILs relative to baseline tumor volume and monitored their persistence in the peripheral blood for up to 24 months after infusion. Results:Responding patients received a higher absolute number of CD8+TCRαβ+ T cells than nonresponders (P = 0.0290). The frequency of infusion product CD8+TCRαβ+ T cells was strongly associated with PFS at 6 months (P < 0.0001). The number of tumor-reactive CD8+ T cells infused, normalized to baseline tumor burden, correlated with BOR (P = 0.0352) and PFS at 6 months (P = 0.0007), with sustained peripheral blood persistence of tumor-reactive CD4+ and CD8+ T cells predictive of durable clinical response. Conclusions:CD8+ T-cell phenotype, tumor reactivity, and in vivo persistence emerged as strong predictors of clinical outcome. Our data identify CD8+ T cells as a key determinant of therapeutic efficacy.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Purpose:Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is a highly personalized cancer immunotherapy. In the randomized phase III clinical trial [TIL-Netherlands Cancer Institute (NKI)/National Center for Cancer Immune Therapy (CCIT)], TIL therapy significantly improved progression-free survival (PFS) compared with ipilimumab in patients with unresectable stage IIIC and IV cutaneous melanoma. This study aimed to define the phenotypic and functional characteristics of the infused TIL associated with the best overall response (BOR) and PFS. Experimental Design:Using flow cytometry, we profiled infusion products from all 80 patients treated with TILs in the TIL-NKI/CCIT trial and correlated the results with BOR and PFS. We established autologous tumor cell lines from 24 patients and assessed the antitumor reactivity of the infused CD4+ and CD8+ T cells through coculture assays and intracellular cytokine staining. We quantified tumor-reactive TILs relative to baseline tumor volume and monitored their persistence in the peripheral blood for up to 24 months after infusion. Results:Responding patients received a higher absolute number of CD8+TCRαβ+ T cells than nonresponders (P = 0.0290). The frequency of infusion product CD8+TCRαβ+ T cells was strongly associated with PFS at 6 months (P < 0.0001). The number of tumor-reactive CD8+ T cells infused, normalized to baseline tumor burden, correlated with BOR (P = 0.0352) and PFS at 6 months (P = 0.0007), with sustained peripheral blood persistence of tumor-reactive CD4+ and CD8+ T cells predictive of durable clinical response. Conclusions:CD8+ T-cell phenotype, tumor reactivity, and in vivo persistence emerged as strong predictors of clinical outcome. Our data identify CD8+ T cells as a key determinant of therapeutic efficacy.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S19 from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Figure S1: Gating strategy Flow Panel 1. Supplementary Figure S2: Gating strategy Flow Panel 2 Supplementary Figure S3: Gating strategy Flow Panel 3 Supplementary Figure S4: Gating strategy Flow Panel 3 Supplementary Figure S5: Verification of patient-derived melanoma tumor cell lines using immunohistochemistry staining Supplementary Figure S6: Co-culture controls Supplementary Figure S7: Gating strategy of anti-tumor responses in infusion product T cells following co-culture with their matched autologous tumor cell lines. Supplementary Figure S8: Gating strategy of anti-tumor responses in peripheral blood T cells following co-culture with their matched autologous tumor cell lines. Supplementary Figure S9: Measurement of baseline metabolic tumor volume using whole-body 18FDG PET scans Supplementary Figure S10: Impact of prior anti-PD1 therapy on phenotypic infusion production composition (Part 1) Supplementary Figure S11: Impact of prior anti-PD1 therapy on phenotypic infusion production composition (Part 2) Supplementary Figure S12: Overall composition of the TIL infusion product (TIL-IMP) and its association with progression-free survival Supplementary Figure S13: Expression of IFNy, TNFa, CD107a, and CD137 on CD4+ and CD8+ infusion product T cells after co-culture with their matched autologous tumor cell line Supplementary Figure S14: Anti-tumor responses of CD4+ and CD8+ TIL-IMP T cells Supplementary Figure S15: Impact of estimated baseline MTV on BOR and PFS Supplementary Figure S16: Activation of CD4+ and CD8+ TIL-IMP T cells after stimulation with T cell TransAct or PMA/Ionomycin Supplementary Figure S17: Activation of CD4+ and CD8+ TIL-IMP T cells with T cell TransAct or PMA/Ionomycin Supplementary Figure S18: Expression of MHC Class I (HLA-ABC) and MHC Class II (HLA-DR) on patient-derived TCLs with and without IFNγ pre-stimulation Supplementary Figure S19: PFS curves when stratifying patients by their frequency or absolute number of tumor-reactive CD4+ or CD8+ T cells infused.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S19 from Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Figure S1: Gating strategy Flow Panel 1. Supplementary Figure S2: Gating strategy Flow Panel 2 Supplementary Figure S3: Gating strategy Flow Panel 3 Supplementary Figure S4: Gating strategy Flow Panel 3 Supplementary Figure S5: Verification of patient-derived melanoma tumor cell lines using immunohistochemistry staining Supplementary Figure S6: Co-culture controls Supplementary Figure S7: Gating strategy of anti-tumor responses in infusion product T cells following co-culture with their matched autologous tumor cell lines. Supplementary Figure S8: Gating strategy of anti-tumor responses in peripheral blood T cells following co-culture with their matched autologous tumor cell lines. Supplementary Figure S9: Measurement of baseline metabolic tumor volume using whole-body 18FDG PET scans Supplementary Figure S10: Impact of prior anti-PD1 therapy on phenotypic infusion production composition (Part 1) Supplementary Figure S11: Impact of prior anti-PD1 therapy on phenotypic infusion production composition (Part 2) Supplementary Figure S12: Overall composition of the TIL infusion product (TIL-IMP) and its association with progression-free survival Supplementary Figure S13: Expression of IFNy, TNFa, CD107a, and CD137 on CD4+ and CD8+ infusion product T cells after co-culture with their matched autologous tumor cell line Supplementary Figure S14: Anti-tumor responses of CD4+ and CD8+ TIL-IMP T cells Supplementary Figure S15: Impact of estimated baseline MTV on BOR and PFS Supplementary Figure S16: Activation of CD4+ and CD8+ TIL-IMP T cells after stimulation with T cell TransAct or PMA/Ionomycin Supplementary Figure S17: Activation of CD4+ and CD8+ TIL-IMP T cells with T cell TransAct or PMA/Ionomycin Supplementary Figure S18: Expression of MHC Class I (HLA-ABC) and MHC Class II (HLA-DR) on patient-derived TCLs with and without IFNγ pre-stimulation Supplementary Figure S19: PFS curves when stratifying patients by their frequency or absolute number of tumor-reactive CD4+ or CD8+ T cells infused.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF15
Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Purpose: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is a highly personalized cancer immunotherapy. In the randomized phase III clinical trial [TIL-Netherlands Cancer Institute (NKI)/National Center for Cancer Immune Therapy (CCIT)], TIL therapy significantly improved progression-free survival (PFS) compared with ipilimumab in patients with unresectable stage IIIC and IV cutaneous melanoma. This study aimed to define the phenotypic and functional characteristics of the infused TIL associated with the best overall response (BOR) and PFS. Experimental Design: Using flow cytometry, we profiled infusion products from all 80 patients treated with TILs in the TIL-NKI/CCIT trial and correlated the results with BOR and PFS. We established autologous tumor cell lines from 24 patients and assessed the antitumor reactivity of the infused CD4+ and CD8+ T cells through coculture assays and intracellular cytokine staining. We quantified tumor-reactive TILs relative to baseline tumor volume and monitored their persistence in the peripheral blood for up to 24 months after infusion. Results: Responding patients received a higher absolute number of CD8+TCRαβ+ T cells than nonresponders (P = 0.0290). The frequency of infusion product CD8+TCRαβ+ T cells was strongly associated with PFS at 6 months (P < 0.0001). The number of tumor-reactive CD8+ T cells infused, normalized to baseline tumor burden, correlated with BOR (P = 0.0352) and PFS at 6 months (P = 0.0007), with sustained peripheral blood persistence of tumor-reactive CD4+ and CD8+ T cells predictive of durable clinical response. Conclusions: CD8+ T-cell phenotype, tumor reactivity, and in vivo persistence emerged as strong predictors of clinical outcome. Our data identify CD8+ T cells as a key determinant of therapeutic efficacy.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF15
Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma
Purpose: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is a highly personalized cancer immunotherapy. In the randomized phase III clinical trial [TIL-Netherlands Cancer Institute (NKI)/National Center for Cancer Immune Therapy (CCIT)], TIL therapy significantly improved progression-free survival (PFS) compared with ipilimumab in patients with unresectable stage IIIC and IV cutaneous melanoma. This study aimed to define the phenotypic and functional characteristics of the infused TIL associated with the best overall response (BOR) and PFS. Experimental Design: Using flow cytometry, we profiled infusion products from all 80 patients treated with TILs in the TIL-NKI/CCIT trial and correlated the results with BOR and PFS. We established autologous tumor cell lines from 24 patients and assessed the antitumor reactivity of the infused CD4+ and CD8+ T cells through coculture assays and intracellular cytokine staining. We quantified tumor-reactive TILs relative to baseline tumor volume and monitored their persistence in the peripheral blood for up to 24 months after infusion. Results: Responding patients received a higher absolute number of CD8+TCRαβ+ T cells than nonresponders (P = 0.0290). The frequency of infusion product CD8+TCRαβ+ T cells was strongly associated with PFS at 6 months (P < 0.0001). The number of tumor-reactive CD8+ T cells infused, normalized to baseline tumor burden, correlated with BOR (P = 0.0352) and PFS at 6 months (P = 0.0007), with sustained peripheral blood persistence of tumor-reactive CD4+ and CD8+ T cells predictive of durable clinical response. Conclusions: CD8+ T-cell phenotype, tumor reactivity, and in vivo persistence emerged as strong predictors of clinical outcome. Our data identify CD8+ T cells as a key determinant of therapeutic efficacy.
- 15 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115640
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma
- 15 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115640
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma
- Open Access
- 26 March 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (3) , e008372
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
Introduction In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimumab improved progression-free survival in patients with unresectable stage IIIC–IV melanoma after failure of first-line or second-line treatment. Based on this trial, we conducted a cost-utility analysis. Methods A Markov decision model was constructed to estimate expected costs (expressed in 2021€) and outcomes (quality-adjusted life years (QALYs)) of TIL-NKI/CCIT versus ipilimumab in the Netherlands. The Danish setting was assessed in a scenario analysis. A modified societal perspective was applied over a lifetime horizon. TIL-NKI/CCIT production costs were estimated via activity-based costing. Through sensitivity analyses, uncertainties and their impact on the incremental cost-effectiveness ratio (ICER) were assessed. Results Mean total undiscounted lifetime benefits were 4.47 life years (LYs) and 3.52 QALYs for TIL-NKI/CCIT and 3.33 LYs and 2.46 QALYs for ipilimumab. Total lifetime undiscounted costs in the Netherlands were €347,168 for TIL-NKI/CCIT (including €67,547 for production costs) compared with €433,634 for ipilimumab. Undiscounted lifetime cost in the Danish scenario were €337,309 and €436,135, respectively. This resulted in a dominant situation for TIL-NKI/CCIT compared with ipilimumab in both countries, meaning incremental QALYs were gained at lower costs. Survival probabilities, and utility in progressive disease affected the ICER most. Conclusion Based on the data of a randomized phase 3 trial, treatment with TIL-NKI/CCIT in patients with unresectable stage IIIC–IV melanoma is cost-effective and cost-saving, both in the current Dutch and Danish setting. These findings led to inclusion of TIL-NKI/CCIT as insured care and treatment guidelines. Publicly funded development of the TIL-NKI/CCIT cell therapy shows realistic promise to further explore development of effective personalized treatment while warranting economic sustainability of healthcare systems.
- 26 March 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (3) , e008372
Open AccessCost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
Introduction In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimumab improved progression-free survival in patients with unresectable stage IIIC–IV melanoma after failure of first-line or second-line treatment. Based on this trial, we conducted a cost-utility analysis. Methods A Markov decision model was constructed to estimate expected costs (expressed in 2021€) and outcomes (quality-adjusted life years (QALYs)) of TIL-NKI/CCIT versus ipilimumab in the Netherlands. The Danish setting was assessed in a scenario analysis. A modified societal perspective was applied over a lifetime horizon. TIL-NKI/CCIT production costs were estimated via activity-based costing. Through sensitivity analyses, uncertainties and their impact on the incremental cost-effectiveness ratio (ICER) were assessed. Results Mean total undiscounted lifetime benefits were 4.47 life years (LYs) and 3.52 QALYs for TIL-NKI/CCIT and 3.33 LYs and 2.46 QALYs for ipilimumab. Total lifetime undiscounted costs in the Netherlands were €347,168 for TIL-NKI/CCIT (including €67,547 for production costs) compared with €433,634 for ipilimumab. Undiscounted lifetime cost in the Danish scenario were €337,309 and €436,135, respectively. This resulted in a dominant situation for TIL-NKI/CCIT compared with ipilimumab in both countries, meaning incremental QALYs were gained at lower costs. Survival probabilities, and utility in progressive disease affected the ICER most. Conclusion Based on the data of a randomized phase 3 trial, treatment with TIL-NKI/CCIT in patients with unresectable stage IIIC–IV melanoma is cost-effective and cost-saving, both in the current Dutch and Danish setting. These findings led to inclusion of TIL-NKI/CCIT as insured care and treatment guidelines. Publicly funded development of the TIL-NKI/CCIT cell therapy shows realistic promise to further explore development of effective personalized treatment while warranting economic sustainability of healthcare systems.
- Open Access
- 4 August 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
Background: Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for patients with unresectable stage IIIB-IVM1a melanoma and has the potential to make tumors more susceptible for ICI. Combination ICI and intralesional T-VEC has already been investigated in patients with unresectable stage IIIB-IV disease, however, no data is available yet on the potential benefit of this combination therapy in neoadjuvant setting. Methods: This single center, single arm, phase II study aims to show an improved major pathologic complete response (pCR) rate, either pCR or near-pCR, up to 45% in 24 patients with resectable stage IIIB-IVM1a melanoma upon neoadjuvant combination treatment with intralesional T-VEC and systemic nivolumab (anti-PD-1 antibody). Patients will receive four courses of T-VEC up to 4 mL (first dose as seroconversion dose) and three doses of nivolumab (240 mg flatdose) every 2 weeks, followed by surgical resection in week nine. The primary endpoint of this trial is pathologic response rate. Secondary endpoints are safety, the rate of delay of surgery and event-free survival. Additionally, prognostic and predictive biomarker research and health-related quality of life evaluation will be performed. Discussion: Intralesional T-VEC has the capacity to heighten the immune response and to elicit an abscopal effect in melanoma in combination with ICI. However, the potential clinical benefit of T-VEC plus ICI in the neoadjuvant setting remains unknown. This is the first trial investigating the efficacy and safety of neoadjuvant treatment of T-VEC and nivolumab followed by surgical resection in patients with stage IIIB-IVM1a melanoma, with the potential of high pathologic response rates and acceptable toxicity. Trial registration: This trial was registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT- number: 2019–001911-22) and the Central Committee on Research Involving Human Subjects (NL71866.000.19) on 4th June 2020. Secondary identifying number: NCT04330430.
- 4 August 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Open AccessNeoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
Background: Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for patients with unresectable stage IIIB-IVM1a melanoma and has the potential to make tumors more susceptible for ICI. Combination ICI and intralesional T-VEC has already been investigated in patients with unresectable stage IIIB-IV disease, however, no data is available yet on the potential benefit of this combination therapy in neoadjuvant setting. Methods: This single center, single arm, phase II study aims to show an improved major pathologic complete response (pCR) rate, either pCR or near-pCR, up to 45% in 24 patients with resectable stage IIIB-IVM1a melanoma upon neoadjuvant combination treatment with intralesional T-VEC and systemic nivolumab (anti-PD-1 antibody). Patients will receive four courses of T-VEC up to 4 mL (first dose as seroconversion dose) and three doses of nivolumab (240 mg flatdose) every 2 weeks, followed by surgical resection in week nine. The primary endpoint of this trial is pathologic response rate. Secondary endpoints are safety, the rate of delay of surgery and event-free survival. Additionally, prognostic and predictive biomarker research and health-related quality of life evaluation will be performed. Discussion: Intralesional T-VEC has the capacity to heighten the immune response and to elicit an abscopal effect in melanoma in combination with ICI. However, the potential clinical benefit of T-VEC plus ICI in the neoadjuvant setting remains unknown. This is the first trial investigating the efficacy and safety of neoadjuvant treatment of T-VEC and nivolumab followed by surgical resection in patients with stage IIIB-IVM1a melanoma, with the potential of high pathologic response rates and acceptable toxicity. Trial registration: This trial was registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT- number: 2019–001911-22) and the Central Committee on Research Involving Human Subjects (NL71866.000.19) on 4th June 2020. Secondary identifying number: NCT04330430.
- 20 October 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (43)
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
Significance: Despite the success of checkpoint-targeting therapies, many melanoma patients do not respond or acquire resistance after initial responsiveness. A better understanding about the mechanism by which these therapies enhance immune-mediated tumor control is key to providing the rationale for better treatment strategies. In this study, we show that PD-1 blockade does not modulate the breadth or the magnitude of the circulating tumor-reactive CD8 T cell response. In contrast and in concordance with our previous study, CTLA-4 blockade leads to a broadening of the circulating melanoma-reactive CD8 T cell response. Together, these findings show differential mechanisms of action of CTLA-4 and PD-1 blockade and support the synergy of the combination treatment seen in the clinic.
- 20 October 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (43)
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
Significance: Despite the success of checkpoint-targeting therapies, many melanoma patients do not respond or acquire resistance after initial responsiveness. A better understanding about the mechanism by which these therapies enhance immune-mediated tumor control is key to providing the rationale for better treatment strategies. In this study, we show that PD-1 blockade does not modulate the breadth or the magnitude of the circulating tumor-reactive CD8 T cell response. In contrast and in concordance with our previous study, CTLA-4 blockade leads to a broadening of the circulating melanoma-reactive CD8 T cell response. Together, these findings show differential mechanisms of action of CTLA-4 and PD-1 blockade and support the synergy of the combination treatment seen in the clinic.
- Open Access
- 31 July 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-14
Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
Background: Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared to ipilimumab is still ongoing, adoption of TIL therapy by the field is confronted with uncertainty. To deal with this, scenario drafting can be used to identify potential barriers and enables the subsequent anticipation on these barriers. This study aims to inform adoption decisions of TIL by evaluating various scenarios and evaluate their effect on the cost-effectiveness. Methods: First, 14 adoption scenarios for TIL-therapy were drafted using a Delphi approach with a group of involved experts. Second, the likelihood of the scenarios taking place within 5 years was surveyed among international experts using a web-based questionnaire. Third, based on the questionnaire results and recent literature, scenarios were labeled as being either “likely” or “-unlikely”. Finally, the cost-effectiveness of TIL treatment involving the “likely” scored scenarios was calculated. Results: Twenty-nine experts from 12 countries completed the questionnaire. The scenarios showed an average likelihood ranging from 29 to 58%, indicating that future developments of TIL-therapy were surrounded with quite some uncertainty. Eight of the 14 scenarios were labeled as “likely”. The net monetary benefit per patient is presented as a measure of cost-effectiveness, where a positive value means that a scenario is cost-effective. For six of these scenarios the cost-effectiveness was calculated: “Commercialization of TIL production” (the price was assumed to be 3 times the manufacturing costs in the academic setting) (−€51,550), “Pharmaceutical companies lowering the prices of ipilimumab” (€11,420), “Using TIL-therapy combined with ipilimumab” (−€10,840), “Automatic TIL production” (€22,670), “TIL more effective” (€23,270), “Less Interleukin-2” (€20,370). Conclusions: Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of “likely” scenarios. These scenarios could function as facilitators for adoption. Contrary, TIL therapy was expected to not be cost-effective when sold at commercial prices, or when combined with ipilimumab. These scenarios should be considered in the adoption decision as these may act as crucial barriers.
- 31 July 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-14
Open AccessEvaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
Background: Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared to ipilimumab is still ongoing, adoption of TIL therapy by the field is confronted with uncertainty. To deal with this, scenario drafting can be used to identify potential barriers and enables the subsequent anticipation on these barriers. This study aims to inform adoption decisions of TIL by evaluating various scenarios and evaluate their effect on the cost-effectiveness. Methods: First, 14 adoption scenarios for TIL-therapy were drafted using a Delphi approach with a group of involved experts. Second, the likelihood of the scenarios taking place within 5 years was surveyed among international experts using a web-based questionnaire. Third, based on the questionnaire results and recent literature, scenarios were labeled as being either “likely” or “-unlikely”. Finally, the cost-effectiveness of TIL treatment involving the “likely” scored scenarios was calculated. Results: Twenty-nine experts from 12 countries completed the questionnaire. The scenarios showed an average likelihood ranging from 29 to 58%, indicating that future developments of TIL-therapy were surrounded with quite some uncertainty. Eight of the 14 scenarios were labeled as “likely”. The net monetary benefit per patient is presented as a measure of cost-effectiveness, where a positive value means that a scenario is cost-effective. For six of these scenarios the cost-effectiveness was calculated: “Commercialization of TIL production” (the price was assumed to be 3 times the manufacturing costs in the academic setting) (−€51,550), “Pharmaceutical companies lowering the prices of ipilimumab” (€11,420), “Using TIL-therapy combined with ipilimumab” (−€10,840), “Automatic TIL production” (€22,670), “TIL more effective” (€23,270), “Less Interleukin-2” (€20,370). Conclusions: Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of “likely” scenarios. These scenarios could function as facilitators for adoption. Contrary, TIL therapy was expected to not be cost-effective when sold at commercial prices, or when combined with ipilimumab. These scenarios should be considered in the adoption decision as these may act as crucial barriers.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , 9587
Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.
9587 Background: The aim of this study is to evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib and trametinib (BRAF and MEK inhibitor respectively) to allow radical surgical resection in patients with unresectable BRAF-mutated, locally advanced stage III or oligometastatic stage IV melanoma. Methods: A total of 25 patients with BRAF-mutated, unresectable locally advanced stage III or oligometastatic stage IV (≤3 metastases) melanoma will be treated with dabrafenib and trametinib for 8 weeks. Response evaluation by positron emission tomography/computed tomography (PET/CT) will occur at 2 and 8 weeks. If sufficient downsizing occurs, surgical resection will be performed. Biopsies for translational research will be taken at baseline and 2 weeks. The dissection specimen will be stored at 8 weeks. Results: Currently 20 patients have been included. Of these, 2 patients showed PD upon treatment and did not proceed to surgery. In 17/18 (94%) patients resection was possible after neoadjuvant treatment, of which 16 (94%) were R0 resections. Median follow-up time is 28 months with a median recurrence free survival of 9 months in patients undergoing surgery. The 1-year overall survival (OS) was 94% and 2-year OS 82%. Median OS was not reached. Metabolic response rates (RR) on PET/CT at 8 weeks were: 4 (20%) CR, 14 (70%) PR, 0 (0%) SD, 2 (10%) PD. Pathologic RR differed: 7 (35%) CR, 7 (35%) PR, 3 (15%) SD, 0 (0%) PD and in 3 patients (15%) no pathologic response was measured, since no resection was performed. Most patients (85%) experienced any toxicity, of which 50% was grade 1, 20% grade 2 and 3 patients (15%) experienced grade 3 toxicity. The most common reported toxicity was fever. Conclusions: Neoadjuvant dabrafenib and trametinib shows to be a potent cytoreductive treatment, allowing radical resection of metastases in 16/20 (80%) patients with prior unresectable locally advanced melanoma. Patients with no recurrence remained disease-free for a prolonged period of time. If there was recurrent disease, this usually occurred within months after surgery and this may present an opportunity for further tailored adjuvant therapy. Clinical trial information: NTR4654.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , 9587
Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.
9587 Background: The aim of this study is to evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib and trametinib (BRAF and MEK inhibitor respectively) to allow radical surgical resection in patients with unresectable BRAF-mutated, locally advanced stage III or oligometastatic stage IV melanoma. Methods: A total of 25 patients with BRAF-mutated, unresectable locally advanced stage III or oligometastatic stage IV (≤3 metastases) melanoma will be treated with dabrafenib and trametinib for 8 weeks. Response evaluation by positron emission tomography/computed tomography (PET/CT) will occur at 2 and 8 weeks. If sufficient downsizing occurs, surgical resection will be performed. Biopsies for translational research will be taken at baseline and 2 weeks. The dissection specimen will be stored at 8 weeks. Results: Currently 20 patients have been included. Of these, 2 patients showed PD upon treatment and did not proceed to surgery. In 17/18 (94%) patients resection was possible after neoadjuvant treatment, of which 16 (94%) were R0 resections. Median follow-up time is 28 months with a median recurrence free survival of 9 months in patients undergoing surgery. The 1-year overall survival (OS) was 94% and 2-year OS 82%. Median OS was not reached. Metabolic response rates (RR) on PET/CT at 8 weeks were: 4 (20%) CR, 14 (70%) PR, 0 (0%) SD, 2 (10%) PD. Pathologic RR differed: 7 (35%) CR, 7 (35%) PR, 3 (15%) SD, 0 (0%) PD and in 3 patients (15%) no pathologic response was measured, since no resection was performed. Most patients (85%) experienced any toxicity, of which 50% was grade 1, 20% grade 2 and 3 patients (15%) experienced grade 3 toxicity. The most common reported toxicity was fever. Conclusions: Neoadjuvant dabrafenib and trametinib shows to be a potent cytoreductive treatment, allowing radical resection of metastases in 16/20 (80%) patients with prior unresectable locally advanced melanoma. Patients with no recurrence remained disease-free for a prolonged period of time. If there was recurrent disease, this usually occurred within months after surgery and this may present an opportunity for further tailored adjuvant therapy. Clinical trial information: NTR4654.